HBW
IART icon

Hazlett, Burt & Watson’s Integra LifeSciences IART Stock Holding History

Hazlett, Burt & Watson’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-925
Closed -$9K – 920
2026
Q1 		$9K Hold
925
– – ﹤0.01% 708
2025
Q4 		$11K Hold
925
– – ﹤0.01% 692
2025
Q3 		$13K Buy
+925
New +$12.7K ﹤0.01% 623

Other funds holding IART

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Hazlett, Burt & Watson's IART Position: Q2 2026 in Review

Hazlett, Burt & Watson sold out of Integra LifeSciences (IART) in Q2 2026, closing a stake of 925 shares — an estimated $9K sold.

Hazlett, Burt & Watson first reported a position in IART in Q3 2025 and held it in 3 quarters. The position peaked at $13K in Q3 2025. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

  • Hazlett, Burt & Watson reported no remaining Integra LifeSciences position as of Q2 2026 after selling out during the quarter.
  • Hazlett, Burt & Watson sold 925 Integra LifeSciences shares in Q2 2026, an estimated $9K.
  • Hazlett, Burt & Watson first reported a position in Integra LifeSciences in Q3 2025 and held it in 3 quarters.
  • Hazlett, Burt & Watson's Integra LifeSciences position peaked at $13K in Q3 2025.
  • 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.